How to appeal a UnitedHealthcare amyloidosis (cardiac attr + al) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for amyloidosis (cardiac attr + al)

Cited policy: OptumRx Vyndaqel / Vyndamax (Tafamidis) Prior Authorization for ATTR-CM

Adult (>=18). Diagnosis of wild-type or hereditary ATTR cardiomyopathy confirmed by EITHER (a) Tc-99m-PYP / DPD / HMDP scan Perugini grade 2 or 3 with H/CL >=1.5 PLUS negative monoclonal protein screen (SPEP + UPEP + sFLC ratio + serum/urine immunofixation), OR (b) endomyocardial / extracardiac biopsy with Congo-red apple-green birefringence + mass-spec typing identifying TTR. NYHA class I-III. Prescribed by cardiologist with amyloidosis expertise. Reauth annually with NYHA + 6MWD + NT-proBNP.

How UnitedHealthcare denies amyloidosis (cardiac attr + al) — and how to counter it

Where UnitedHealthcare pushes back: 1) Endomyocardial biopsy required regardless of PYP; 2) Tafamidis only Class IIa — not first-line; 3) ATTRwt or ATTRv not specified / TTR genotype missing; 4) Step-therapy: ARB / diuretic / GDMT first; 5) NYHA IV or advanced disease excluded.

Counter-arguments that hold up: Gillmore Circulation 2016 + AHA 2020 Scientific Statement (Kittleson Circulation 2020) + ESC 2023 consensus: PYP grade 2-3 with H/CL >=1.5 + negative monoclonal screen = sufficient non-invasive ATTR-CM dx (specificity 100%). ACC/AHA/HFSA 2022 (Heidenreich Circulation 2022) Class IIa LOE B-R is highest single-trial recommendation; ATTR-ACT (Maurer NEJM 2018) 30% all-cause mortality reduction NNT 7-9. ATTRwt and ATTRv both labeled. ARBs/ACEIs poorly tolerated in restrictive ATTR per Kittleson 2020. NYHA III enrolled in ATTR-ACT (subset benefit weaker but present); NYHA IV requires individualized review.

What UnitedHealthcare typically denies for amyloidosis (cardiac attr + al)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyndaqel / Vyndamax (tafamidis)
• Attruby (acoramidis)
• Amvuttra (vutrisiran) ATTR-CM
• Onpattro (patisiran)
• Wainua (eplontersen)
• D-VCd for AL

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.